Entero Healthcare Solu L
NSE: ENTERO · Retailing · sector
₹1,475.10NSE close 2026-10-26
Key numbers
Market cap₹6,420 cr
Price₹1,475.10
52w high / low₹1,920 / ₹944
P/E51.2xSector median 42.9x
P/B3.8xSector median 3.8x
Book value₹388.0
Dividend yield–
ROE7.3%Sector median 9.3%
ROCE12.2%Sector median 16.0%
OPM4.3%Sector median 6.4%
Debt / equity0.34xSector median 0.17x
EV/EBITDA22.0xSector median 16.6x
Interest cover4.3x
Current ratio1.58x
Sales growth 3y–Sector median +14.8%
Profit growth 3y–Sector median +64.0%
PEG2.29x
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 2 companies in Retailing (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹292 cr vs borrowings ₹567 cr (FY26): borrowings are higher by ₹275 cr.
- Operating profit covered interest 4.3x in the last 12 months.
- Operating cash flow was below net profit in 3 of the last 3 years (FY26, FY25, FY24).
- Revenue was higher than a year earlier in 4 of the last 4 quarters.
- Other income was 13% of net profit in the last 12 months.
- Debtor days went from 57 (FY24) to 67 (FY26).
- No dividend in the last 3 financial years.
- Price ₹1,475.10 on 2026-10-26: -23.2% from the 52-week high, +56.3% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹1,852.20 · low ₹962.50
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,301 | 1,359 | 1,339 | 1,404 | 1,571 | 1,707 | 1,910 | 1,940 |
| EBITDA | 42 | 50 | 49 | 50 | 62 | 60 | 86 | 97 |
| OPM % | 3.3% | 3.7% | 3.7% | 3.6% | 4.0% | 3.5% | 4.5% | 5.0% |
| Other income | 11 | 8 | 7 | 6 | 5 | 5 | 4 | 3 |
| Net profit | 24 | 25 | 26 | 28 | 32 | 28 | 28 | 38 |
| EPS (₹) | 5.43 | 5.85 | 5.91 | 6.39 | 7.26 | 6.35 | 6.44 | 8.77 |
| Revenue YoY | +20.8% | +25.6% | +42.6% | +38.2% | ||||
| Profit YoY | +33.8% | +8.6% | +9.0% | +37.3% |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|
| Revenue | 3,922 | 5,096 | 6,591 | 7,128 |
| EBITDA | 112 | 172 | 258 | 305 |
| Net profit | 39 | 95 | 115 | 125 |
| EPS (₹) | 10.81 | 21.80 | 26.44 | 28.82 |
| Revenue growth | +29.9% | +29.3% | +31.9% | |
| Profit growth | +142.4% | +21.3% | +22.3% | |
| Dividend / share (₹) | – | – | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | – | – | +31.9% |
| Net profit | – | – | +22.3% |
| EPS | – | – | – |
| Share price | – | +3.7% (2y) | +32.2% |
Balance sheet
| ₹ cr | FY24 | FY25 | FY26 |
|---|---|---|---|
| Shareholders' equity | 1,638 | 1,724 | 1,689 |
| Borrowings | 276 | 299 | 567 |
| Cash & equivalents | 893 | 318 | 292 |
| Total assets | 2,345 | 2,703 | 3,600 |
| Fixed assets | 93 | 132 | 103 |
| Capital work in progress | – | 0 | 0 |
| Investments | 0 | 0 | 0 |
| Receivables | 615 | 830 | 1,212 |
| Inventory | 421 | 660 | 842 |
| Payables | 230 | 397 | 725 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY24 | FY25 | FY26 |
|---|---|---|---|
| Cash from operations | -37 | -77 | 96 |
| Cash from investing | -705 | 220 | -303 |
| Cash from financing | 863 | -74 | 124 |
| Capex | 5 | 11 | 68 |
| Free cash flow | -42 | -88 | 29 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY24 | FY25 | FY26 |
|---|---|---|---|
| ROE % | 2.4% | 5.5% | 6.8% |
| ROCE % | 5.3% | 8.9% | 10.4% |
| Debtor days | 57 | 59 | 67 |
| Inventory days | 43 | 52 | 52 |
| Payable days | 24 | 31 | 45 |
| Cash conversion cycle (days) | 76 | 80 | 74 |
| Working capital days | 131 | 88 | 51 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 52.40% |
| FIIs | 5.77% |
| DIIs | 21.16% |
| of which Mutual funds | 11.15% |
| of which Insurance | 0.01% |
| Public (non-institutions) | 20.67% |
| Quarter | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters % | 52.44% | 52.42% | 52.42% | 52.42% | 52.42% | 52.42% | 52.40% | 52.40% |
| Promoter group | % |
|---|---|
| Orbimed Asia III Mauritius Limited | 38.00% |
| Prabhat Agrawal | 9.26% |
| Prem Sethi | 5.15% |
| Richa Agarwal | 0.00% |
| Arti Mittal | 0.00% |
| Payal Agrawal | 0.00% |
| Kunjbehari lal Agrawal | 0.00% |
| Asha Agrawal | 0.00% |
| Neha Agrawal | 0.00% |
| Jaibhagwan Mittal | 0.00% |
| Komal Gupta | 0.00% |
| Kunal Mittal | 0.00% |
| Vikas Sethi | 0.00% |
| Lubna Sethi | 0.00% |
| Shweta Adlakha | 0.00% |
| Public holders above 1% | % |
|---|---|
| HDFC Mutual Fund - HDFC Pharma and Healthcare Fund | 3.19% |
| Invesco India Contra Fund | 3.19% |
| Surbhi Singh(prasid UNO Family Trust) | 3.05% |
| 3P India Equity Fund 1 | 3.03% |
| Bank of India Flexi CAP Fund | 2.40% |
| CIF III Scheme I | 1.53% |
| 3P India Equity Fund 1M | 1.18% |
| Ajay Kumar Aggarwal | 1.01% |
40,919 shareholders. Pledged: – of promoter shares.
Peers in Retailing
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| MEDPLUS | ₹7,306 cr | 34.7x | 3.7x | 11.3% | 19.8% | 8.4% | +14.8% | – |
| ENTERO | ₹6,420 cr | 51.2x | 3.8x | 7.3% | 12.2% | 4.3% | – | – |
Documents
- Annual report FY26
- Annual report FY25
- Annual report FY24
- Announcements NSE filings
- BRSR FY26
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
- The Company and its subsidiaries are engaged in the Business of Distribution and Marketing of Pharmaceuticals, Surgical and other Healthcare and Allied products.: Distribution and Marketing of Pharmaceuticals, Surgical and other Healthcare and Allied products.
| Sector | Consumer Discretionary |
| Industry | Retailing |
| Sub-industry | Pharmacy Retail |
| Symbol | ENTERO |
| BSE code | 544122 |
| ISIN | INE010601016 |
| Face value | ₹10.0 |
| Incorporated | 2018-01-10 |
| Website | www.enterohealthcare.com |
| Plants (India / abroad) | 0 / 0 |
From the company's filings (BRSR FY26).
Data built 2026-10-22 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.